Chemiluminescence Immunoassay Market Report 2026

The chemiluminescence immunoassay market size has grown strongly in recent years. It will grow from $14.85 billion in 2025 to $16.15 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing prevalence of infectious and chronic diseases, expansion of centralized diagnostic laboratories, rising demand for accurate biomarker detection, wider adoption of automated laboratory systems, growing use of immunoassays in clinical diagnostics.

The chemiluminescence immunoassay market size is expected to see strong growth in the next few years. It will grow to $22.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for early disease detection, rising adoption of personalized medicine diagnostics, expansion of decentralized testing models, growing integration of ai-assisted diagnostic interpretation, increasing investment in advanced clinical laboratory infrastructure. Major trends in the forecast period include increasing adoption of fully automated immunoassay analyzers, rising demand for high-sensitivity diagnostic kits, growing use of multiplex testing capabilities, expansion of rapid and point-of-care clia systems, enhanced focus on standardized reagent performance.

The rising prevalence of infectious diseases is expected to drive the growth of the chemiluminescence immunoassay market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from person to person either directly or indirectly. The prevalence of infectious diseases is increasing due to the rise in antimicrobial resistance, which makes standard treatments less effective, allowing infections to persist and spread. Chemiluminescence immunoassays support infectious disease diagnosis by providing highly sensitive and specific biomarker detection, enabling early and accurate identification of pathogens. They reduce diagnostic delays by delivering rapid and reliable results, improving patient management and treatment outcomes. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government body, tuberculosis (a contagious bacterial infection primarily affecting the lungs) cases in England increased to 4,850 in 2023, up 10.7% from 4,380 cases in 2022. Therefore, the growing prevalence of infectious diseases is driving the growth of the chemiluminescence immunoassay market.

Major companies operating in the chemiluminescence immunoassay market are focusing on developing advanced products, such as next-generation chemiluminescence immunoassay analyzers, to improve test accuracy, increase throughput, and deliver faster diagnostic results across various clinical applications. Chemiluminescence immunoassay analyzers are automated instruments that detect and quantify light emitted during chemical reactions to precisely identify specific biomarkers in diagnostic tests. For instance, in July 2023, Fapon Biotech Inc., a China-based biotechnology company, launched the Shine i8000/9000, a chemiluminescence immunoassay analyzer designed for medium to large laboratories. It provides rapid preliminary results within 10 minutes, offering high precision in a compact, stable, and user-friendly design. Key features include a 360-degree large-span display, one-touch bulk loading of reaction cups, a dual-tube backup substrate system, and automatic reaction cup disposal to minimize contamination. Its fully automated workflow reduces manual intervention, while advanced algorithms ensure consistent results, making it suitable for high-volume diagnostic environments.

In December 2023, Danaher Corporation, a US-based life sciences and diagnostics company, acquired Abcam Limited for approximately $5.7 billion. Through this acquisition, Danaher aims to strengthen its Life Sciences segment by utilizing Abcam's validated antibodies, reagents, biomarkers, and assays to accelerate drug discovery and disease research, while allowing Abcam to continue operating independently. Abcam Limited is a UK-based life sciences company that provides chemiluminescence immunoassay kits and reagents.

Major companies operating in the chemiluminescence immunoassay market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., DiaSorin S.p.A., Tecan Group Ltd., Euroimmun AG, Randox Laboratories Ltd., Autobio Diagnostics Co. Ltd., Wondfo Biotech Co. Ltd., Fujirebio Diagnostics Inc., Trivitron Healthcare Pvt. Ltd., Getein Biotech Inc., Fapon Biotech Inc., Diazyme Laboratories Inc.

North America was the largest region in the chemiluminescence immunoassay market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemiluminescence immunoassay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemiluminescence immunoassay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chemiluminescence immunoassay market by increasing costs of imported analyzers, optical sensors, precision electronics, specialty reagents, and automated laboratory components used across diagnostic platforms. Clinical laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-precision diagnostic equipment, while Asia-Pacific faces cost pressures on reagent manufacturing and exports. These tariffs are increasing procurement costs and slowing laboratory upgrades. However, they are also encouraging local manufacturing of diagnostic instruments, regional reagent production, and supply chain diversification to ensure long-term testing availability.

The chemiluminescence immunoassay market research report is one of a series of new reports that provides chemiluminescence immunoassay market statistics, including chemiluminescence immunoassay industry global market size, regional shares, competitors with a chemiluminescence immunoassay market share, detailed chemiluminescence immunoassay market segments, market trends and opportunities, and any further data you may need to thrive in the chemiluminescence immunoassay industry. This chemiluminescence immunoassay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemiluminescence immunoassay is a biochemical technique used to detect and quantify specific molecules, such as proteins, hormones, or pathogens, by combining antigen-antibody reactions with a chemiluminescent signal. In this method, light is emitted during a chemical reaction and measured to indicate the presence and concentration of the target analyte. It provides highly sensitive, specific, and rapid diagnostic testing in clinical and research applications.

The primary types of products in chemiluminescence immunoassay are analyzers, kits, and reagents. Analyzers are specialized automated instruments designed to perform chemiluminescence immunoassay tests by detecting and measuring the light emitted during the chemical reaction. It encompasses sample types such as blood, saliva, urine, and others, and utilizes various technologies, including chemiluminescence enzyme immunoassay (CLEIA), electrochemiluminescence immunoassay (ECLI), and microparticle chemiluminescence immunoassay. It finds applications in therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease, autoimmune disease, and others, serving diverse end users, including hospitals, pharmaceutical and biotechnology companies, clinical laboratories, and others.

The chemiluminescence immunoassay market consists of revenues earned by entities by providing services such as high-sensitivity diagnostic testing, disease biomarker detection, clinical laboratory workflow optimization, and personalized healthcare diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemiluminescence immunoassay market also includes sales of immunoassay analyzers, control and calibration solutions, diagnostic consumables, and related accessories used for performing chemiluminescence-based diagnostic tests. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.